March 4, 2022

Research Supports Minimally Invasive Surgery for Older Patients with Endometrial Cancer

Study shows improved outcomes over open surgery

robotic surgery for hysterectomy

Endometrial carcinoma is one of the most common gynecological cancers in patients over 65, but it hasn’t always been treated as aggressively in them as it has in those who are younger. A recent study involving the largest patient cohort to date confirmed that laparoscopy and robotic surgery offer increased longevity compared to laparotomy.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The results, say researchers, support the contemporary trend in bringing aggressive interventions to a patient population that once was assumed to be less interested in undergoing surgery for the disease.

“This research responds to a very basic clinical questions that we face as a gynecologic oncologist,” says Joel Cardenas Goicoechea, MD, MBA, a specialist in Gynecologic Oncology at Cleveland Clinic Florida. “When we see patients diagnosed with endometrial cancer in their golden years, how do we intervene? The main purpose of the study was to evaluate whether a particular surgical intervention has benefits for survival.”

The study, Survival after Minimally Invasive Surgery in Older Women with Endometrial Carcinoma, was published in Anticancer Research 42: 75-85 (2022). Dr. Cardenas-Goicoechea was first author on the manuscript.

The research holds an important message for primary care physicians, gynecologists, and for patients themselves, Dr. Cardenas-Goicoechea says.

“Sometimes patients feel they are too old to have surgery, even if it’s for a disease that we can cure,” he says. “We cite a survey that specifically asked older patients if they want to be as aggressive with treatment as younger patients. The answer was yes, but the perception among some physicians was that older patients would say, no, I don’t want to do anything.”

Some of that might be holdover from when the standard surgical treatment was laparotomy, which holds an increased risk of infection and typically requires a longer hospital stay. Those risks are reduced in hysterectomies performed with laparoscopy or robotics, which have become standard over the last decade.


Background on the study

The researchers used data from the National Cancer Database, which is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society, to identify 42,458 women over 65 with endometrial cancer who underwent hysterectomy as the first line of treatment from 2010 to 2015. Median age at diagnosis was 71. The surgery entailed total hysterectomy, bilateral salpingo-oophorectomy, and lymph node assessment.

Within that cohort, 12,099 underwent open surgery; 7,898 had laparoscopic surgery, and 22,461 had the robotic procedure.

Five-year survival rates were the primary focus. Other outcomes reviewed included unplanned readmission, 30-day and 90-day mortality rates, and length of hospital stay.

Key results:

  • The 90-day mortality rate was twice as high for those who had open surgery as for those in the robotic group (2.3% v. 1.2%).
  • The 30-day re-admission rates were 2% (robotic), 2.1% (laparoscopic), and 3.2% (open).
  • MIGS was associated with improved overall survival in older women with endometrial cancer. The estimated five-year survival rates were 73.1% (open), 76.4% (laparoscopic) and 75.5% (robotic).
  • Laparoscopic surgery was associated with 14% higher survival rates and the robotic approach was associated with 12% higher survival compared to rates for open surgery.
  • Although the study did not attempt a head-to-head comparison between laparoscopy and robotic surgeries, data suggest that robotic surgery outperformed laparoscopy in conversion rates. While 8.5% of the laparoscopies were converted to open surgeries, only 1.9% of robotic surgeries were converted. “The message is not that that robotic is superior to laparoscopy, but it’s interesting to see the data across United States,” says Dr. Cardenas-Goicoechea.

In 2021, researchers estimate, there were more than 66,570 new cases of endometrial cancer and 12,940 deaths from uterine cancer in the United States.

“Life expectancy for women in the United States is up to around 81 years old,” says Dr. Cardenas-Goicoechea. “We have to think about helping those patients who are older and dealing with a common gynecologic cancer that has the best prognosis in terms of overall survival.”


Comorbidities common in aging populations — heart disease, stroke, diabetes – must be part of the assessment, but Dr. Cardenas-Goicoechea adds that “as long as those patients can be medically optimized for a two- or three-hour operation, they will be fine. Those patients will enjoy better quality of life and potentially better survival.”

More research is needed to strengthen the understanding of the treatment of older patients with endometrial cancer, because there are biological differences between them and younger patients, Dr. Cardenas-Goicoechea says.

“Older patients are underrepresented in most clinical trials,” he says. “When you do a clinical trial, you have specific criteria you are focusing on, and that may necessitate excluding patients with a history of heart attack, stroke, diabetes or other chronic diseases that are common in the elderly. But we need to find ways to include those patients so we can understand the picture more fully.”

Geriatrics expertise also is needed during treatment and research, Dr. Cardenas-Goicoechea adds.

“Disease management is different in the elderly,” he says. “Patients may need a geriatric evaluation to address issues such as polypharmacy, life expectancy, quality of life, and what needs to be done to medically optimize a patient for a three-hour surgery. All of those kinds of studies need to be done moving forward.”

Related Articles

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival